全球迫切需要检测异常凝血酶原（PIVKA-II）和甲胎蛋白异质体L3（AFP-L3）以监测和管理肝细胞癌 - Suppr

Suppr

超能文献

Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Higashiosaka, Japan.

出版信息

Liver Cancer. 2024 Feb 20;13(2):113-118. doi: 10.1159/000537897. eCollection 2024 Apr.

DOI:10.1159/000537897

PMID:38751558

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11095620/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0c/11095620/7e5ceca23815/lic-2024-0013-0002-537897_F04.jpg

相似文献

Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma.

Liver Cancer. 2024 Feb 20;13(2):113-118. doi: 10.1159/000537897. eCollection 2024 Apr.

Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339.

Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.

Eur J Gastroenterol Hepatol. 2023 Oct 1;35(10):1178-1185. doi: 10.1097/MEG.0000000000002610. Epub 2023 Jul 11.

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis.

J Clin Med. 2022 Aug 29;11(17):5075. doi: 10.3390/jcm11175075.

Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.

Hepatobiliary Pancreat Dis Int. 2022 Dec;21(6):559-568. doi: 10.1016/j.hbpd.2022.05.003. Epub 2022 May 17.

The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma.

J Clin Lab Anal. 2020 May;34(5):e23158. doi: 10.1002/jcla.23158. Epub 2019 Dec 10.

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.

Medicine (Baltimore). 2017 Mar;96(11):e5811. doi: 10.1097/MD.0000000000005811.

Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.

J Gastroenterol. 2007 Dec;42(12):962-8. doi: 10.1007/s00535-007-2117-x. Epub 2007 Dec 25.

Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.

Scand J Gastroenterol. 2016 Mar;51(3):344-53. doi: 10.3109/00365521.2015.1082190. Epub 2015 Sep 4.

[Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].

Zhonghua Gan Zang Bing Za Zhi. 2019 Aug 20;27(8):634-637. doi: 10.3760/cma.j.issn.1007-3418.2019.08.009.

引用本文的文献

as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications.

Curr Issues Mol Biol. 2025 Jul 18;47(7):563. doi: 10.3390/cimb47070563.

The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.

Biomolecules. 2025 Jul 14;15(7):1011. doi: 10.3390/biom15071011.

Prognostic Value of Des-Gamma-Carboxy Prothrombin in AFP-Negative Hepatocellular Carcinoma Patients Following Liver Resection: .

J Cancer. 2025 Jun 12;16(8):2680-2689. doi: 10.7150/jca.112394. eCollection 2025.

The Diagnostic Performance of AFP, AFP-L3, DCP, CA199, and Their Combination for Primary Liver Cancer.

J Hepatocell Carcinoma. 2025 Mar 6;12:513-526. doi: 10.2147/JHC.S499966. eCollection 2025.

Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection.

Langenbecks Arch Surg. 2025 Mar 6;410(1):89. doi: 10.1007/s00423-025-03650-7.

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

Liver Cancer. 2024 Aug 12;13(5):459-467. doi: 10.1159/000540801. eCollection 2024 Oct.

Expression and diagnostic value of abnormal prothrombin and osteopontin in hepatocellular carcinoma with cirrhosis.

Am J Transl Res. 2024 Sep 15;16(9):4688-4695. doi: 10.62347/LHSF1117. eCollection 2024.

CD206 accelerates hepatocellular carcinoma progression by regulating the tumour immune microenvironment and increasing M2-type polarisation of tumour-associated macrophages and inflammation factor expression.

Discov Oncol. 2024 Sep 13;15(1):439. doi: 10.1007/s12672-024-01309-1.

本文引用的文献

A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.

Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb.

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.

Liver Cancer. 2023 Jul 28;12(4):289-296. doi: 10.1159/000532023. eCollection 2023 Sep.

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.

Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep.

Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.

Liver Cancer. 2023 Mar 9;12(2):95-102. doi: 10.1159/000530079. eCollection 2023 Jun.

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).

Hepatol Res. 2023 May;53(5):383-390. doi: 10.1111/hepr.13892. Epub 2023 Mar 10.

The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.

Clin Gastroenterol Hepatol. 2023 Feb;21(2):415-423.e4. doi: 10.1016/j.cgh.2022.01.047. Epub 2022 Feb 3.

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.

Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.

Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis.

Hepatol Res. 2021 May;51(5):548-553. doi: 10.1111/hepr.13626. Epub 2021 Mar 19.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):728-735.e4. doi: 10.1016/j.cgh.2019.11.012. Epub 2019 Nov 8.

Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.

Oncology. 2019;97(2):75-81. doi: 10.1159/000499715. Epub 2019 Jun 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验